AO 120 (Rev. 08/10)

TO:

Mail Stop 8 Director of the U.S. Patent and Trademark Office P.O. Box 1450 Alexandria, VA 22313-1450

REPORT ON THE FILING OR DETERMINATION OF AN ACTION REGARDING A PATENT OR TRADEMARK

Alexandria, VA 22313-1450		TRADEMARK
filed in the U.S. Dist		S.C. § 1116 you are hereby advised that a court action has been the District of Delaware on the following avolves 35 U.S.C. § 292.):
DOCKET NO. 19-1955-LPS	DATE FILED 10/15/2019 U	.s. DISTRICT COURT for the District of Delaware
PLAINTIFF	EUTICAL CO., LTD. and	H. TEVA PHARMACEUTICALS USA, INC. and TEVA PHARMACEUTICAL INDUSTRIES LTD.
PATENT OR TRADEMARK NO.	DATE OF PATENT OR TRADEMARK	HOLDER OF PATENT OR TRADEMARK
1 7,888,362	02/15/2011	Otsuka Pharmaceutical Co., Ltd.
2 8,349,840	01/08/2013	Otsuka Pharmaceutical Co., Ltd.
3 8,618,109	12/31/2013	Otsuka Pharmaceutical Co., Ltd.
4 9,839,637	12/12/2017	Otsuka Pharmaceutical Co., Ltd.
5 10,307,419	06/04/2019	Otsuka Pharmaceutical Co., Ltd.
PATENT OR TRADEMARK NO. 1	INCLUDED BY Amendm DATE OF PATENT OR TRADEMARK	ent
3		
4		
5		
DECISION/JUDGEMENT	Tudgment and Inj	wn نام
CLERK	(RV) DE	PUTY CLERK DATE
John A. Cerino		4-27-2022

IN THE UNITED STATES DISTRICT COURT FOR THE DISTRICT OF DELAWARE

OTSUKA PHARMACEUTICAL CO., LTD., AND H. LUNDBECK A/S,)))
Plaintiffs, v. ZENARA PHARMA PRIVATE LTD., et al. Defendant.)) C.A. No. 19-1938-LPS (consolidated)) C.A. No. 19-1955-LPS) C.A. No. 20-1423-LPS))
OTSUKA PHARMACEUTICAL CO., LTD., AND H. LUNDBECK A/S, Plaintiffs,))))
V.) C.A. No. 22-221-LPS)
TEVA PHARMACEUTICALS USA, INC., and TEVA PHARMACEUTICAL INDUSTRIES LTD.,)))
Defendants.	,)

STIPULATED CONSENT JUDGMENT AND INJUNCTION (Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd.)

IT IS HEREBY STIPULATED AND AGREED, by and between Plaintiffs Otsuka Pharmaceutical Co., Ltd. ("Otsuka") and H. Lundbeck A/S and Defendants Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries Ltd. ("Teva"), through their undersigned counsel of record, that:

1. All claims, counterclaims, affirmative defenses and demands between Otsuka and Teva in these actions are hereby dismissed without prejudice and without costs, disbursements, or attorneys' fees to any party.

2. Teva Pharmaceuticals USA, Inc. and anyone acting on the behalf of Teva Pharmaceuticals USA, Inc., except as expressly licensed by Plaintiffs, will be enjoined until expiration of U.S. Patent No. 8,349,840, U.S. Patent No. 8,618,109, U.S. Patent No. 9,839,637, U.S. Patent No. 10,307,419 and U.S. Reissue Patent No. RE48059 from making, using, offering for sale, selling or importing the products that are the subject of Teva Pharmaceuticals USA, Inc.'s Abbreviated New Drug Application ("ANDA") No. 213692 in the United States.

- Nothing herein prevents FDA from granting final approval to ANDA No. 213692
 at any time.
 - 4. Each party will bear its own attorneys' fees and costs.
- 5. This Court will retain jurisdiction to enforce this Consent Judgment and Injunction and the parties' related agreements resolving these cases.

ASHBY & GEDDES

/s/ Andrew C. Mayo

Steven J. Balick (#2114) Andrew C. Mayo (#5207) 500 Delaware Avenue, 8th Floor P.O. Box 1150 Wilmington, DE 19899 (302) 654-1888 sbalick@ashbygeddes.com amayo@ashbygeddes.com

Attorneys for Plaintiffs Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S

SHAW KELLER LLP

/s/ Nathan R. Hoeschen

John W. Shaw (#3362)
Karen E. Keller (#4489)
Nathan R. Hoeschen (#6232)
I.M. Pei Building
1105 North Market Street, 12th Floor
Wilmington, Delaware 19801
(302) 298-0700
jshaw@shawkeller.com
kkeller@shawkeller.com
nhoeschen@shawkeller.com

Attorneys for Defendant Teva Pharmaceutical USA, Inc. and Teva Pharmaceutical Industries Ltd.

O ORDERED this day o

, 2022.

United States District Judge